Mixed
Triple receptor agonists (GLP-1/GIP/Glucagon) such as retatrutide achieve superior weight loss (20-24%) compared to single or dual agonists by synergistically combining satiety, nutrient partitioning, and increased energy expenditure.
If you are struggling with current GLP-1 therapies or need more aggressive weight loss, triple-agonist medications like retatrutide are the next step. They work by hitting three metabolic targets at once, leading to much higher weight loss (up to 24%) than standard drugs. This is currently an injectable treatment, but oral alternatives are being developed.
These agents leverage complementary mechanisms:GLP-1R activation drives satiety and appetite suppression, GIP receptor activation enhances insulin secretion and may improve nutrient partitioning, while glucagon receptor activation increases energy expenditure and promotes hepatic lipid oxidation [38]. Phase 2 results suggest remarkable weight loss trajectories, that approach or exceed 20-24% (8 and 12 mg) at 48 weeks
Why this rating
Based on Phase 2 trials; Phase 3 results are noted as ongoing.
Source
Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies
Ioannis Lempesis et al. · Metabolism Open · 2026
DOI 10.1016/j.metop.2026.100463
More from this paper
- Oral GLP-1 receptor agonists (e.g., orforglipron) provide comparable efficacy to injectable formulations while improving accessibility by eliminating cold-chain requirements.Moderate
- Combining amylin analogs (e.g., cagrilintide) with GLP-1 agonists (e.g., semaglutide) achieves weight loss (20-22%) through distinct neuroendocrine circuits, offering a tolerability advantage over single agents.Moderate
- Body composition-targeted agents (e.g., bimagrumab) preserve or increase lean mass while reducing fat mass, addressing the functional decline associated with rapid weight loss.Moderate
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →